首页> 美国卫生研究院文献>BMC Biotechnology >A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
【2h】

A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C

机译:有效生产针对HIV-1进化枝C的抗V3人类scFv的新策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundProduction of human monoclonal antibodies that exhibit broadly neutralizing activity is needed for preventing HIV-1 infection, however only a few such antibodies have been generated till date. Isolation of antibodies by the hybridoma technology is a cumbersome process with fewer yields. Further, the loss of unstable or slowly growing clones which may have unique binding specificities often occurs during cloning and propagation and the strongly positive clones are often lost. This has been avoided by the process described in this paper, wherein, by combining the strategy of EBV transformation and recombinant DNA technology, we constructed human single chain variable fragments (scFvs) against the third variable region (V3) of the clade C HIV-1 envelope.
机译:背景技术为了防止HIV-1感染,需要产生具有广泛中和活性的人单克隆抗体,但是迄今为止仅产生了少数这种抗体。用杂交瘤技术分离抗体是一个麻烦的过程,产率较低。此外,在克隆和繁殖期间经常发生可能具有独特结合特异性的不稳定或缓慢生长的克隆的丢失,而强阳性克隆经常丢失。本文所描述的方法避免了这种情况,其中结合EBV转化策略和重组DNA技术,我们针对进化枝C HIV-3的第三个可变区(V3)构建了人单链可变片段(scFvs) 1个信封。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号